Ponatinib Achieves Primary Endpoints in CML Subtypes

Anita T. Shaffer @Shaffer1
Published: Wednesday, Aug 08, 2012
Dr. Jorge E. Cortes

Jorge E. Cortes, MD

Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia (CML) subtypes, in a phase II trial intended to pave the way for a regulatory submission. The benefit reached 70% for some patients with CML who also harbored a T315I gene mutation.

Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol. 2012;30(suppl; abstr 6503).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication